← All stories
Markets
STAT+: How Trump’s latest pharma deals may undermine efforts to rein in drug costs
Analysts say private deals involve drugmakers agreeing to lower prices in Medicaid, where prices are low, in return for no price cuts in Medicare.
Covered by 1 outlet
All coverage · 1 article